Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 457

1.

Research directions in the clinical implementation of pharmacogenomics - An Overview of US programs and projects.

Volpi S, Bult C, Chisholm RL, Deverka PA, Ginsburg GS, Jacob HJ, Kasapi M, McLeod HL, Roden DM, Williams MS, Green ED, Lyman Rodriguez L, Aronson S, Cavallari LH, Denny JC, Dressler L, Johnson JA, Klein TE, Steven Leeder J, Piquette-Miller M, Perera M, Rasmussen-Torvik LJ, Rehm HL, Ritchie MD, Skaar TC, Wagle N, Weinshilboum R, Weitzel KW, Wildin R, Wilson J, Manolio TA, Relling MV.

Clin Pharmacol Ther. 2018 Feb 20. doi: 10.1002/cpt.1048. [Epub ahead of print]

PMID:
29460415
2.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE.

Clin Pharmacol Ther. 2018 Jan 31. doi: 10.1002/cpt.1007. [Epub ahead of print]

PMID:
29385237
3.

Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors.

Gillis NK, Rotroff DM, Mesa TE, Yao J, Chen Z, Carulli MA, Yoder SJ, Walko CM, Teer JK, McLeod HL.

Oncotarget. 2017 Dec 4;8(70):115114-115127. doi: 10.18632/oncotarget.22914. eCollection 2017 Dec 29.

4.

The pharmacogenetics of medications used in general anesthesia.

Xie S, Ma W, Guo Q, Liu J, Li W, McLeod HL, He Y.

Pharmacogenomics. 2018 Feb;19(3):285-298. doi: 10.2217/pgs-2017-0168. Epub 2018 Jan 10.

PMID:
29318929
5.

miR-302b inhibits tumorigenesis by targeting EphA2 via Wnt/ β-catenin/EMT signaling cascade in gastric cancer.

Huang J, He Y, Mcleod HL, Xie Y, Xiao D, Hu H, Chen P, Shen L, Zeng S, Yin X, Ge J, Li L, Tang L, Ma J, Chen Z.

BMC Cancer. 2017 Dec 22;17(1):886. doi: 10.1186/s12885-017-3875-3.

6.

Gene expression and linkage analysis implicate CBLB as a mediator of rituximab resistance.

Jack J, Small GW, Brown CC, Havener TM, McLeod HL, Motsinger-Reif AA, Richards KL.

Pharmacogenomics J. 2017 Dec 5. doi: 10.1038/tpj.2017.41. [Epub ahead of print]

PMID:
29205205
7.

The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer.

Williams GR, Deal AM, Shachar SS, Walko CM, Patel JN, O'Neil B, McLeod HL, Weinberg MS, Choi SK, Muss HB, Sanoff HK.

Cancer Chemother Pharmacol. 2018 Feb;81(2):413-417. doi: 10.1007/s00280-017-3487-2. Epub 2017 Nov 20.

PMID:
29159476
8.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.

Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M.

Clin Pharmacol Ther. 2018 Feb;103(2):210-216. doi: 10.1002/cpt.911. Epub 2017 Nov 20.

PMID:
29152729
9.

Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis.

Manolio TA, Hutter CM, Avigan M, Cibotti R, Davis RL, Denny JC, Grenade L, Wheatley LM, Carrington MN, Chantratita W, Chung WH, Dalton AD, Hung SI, Lee MTM, Leeder JS, Lertora JJL, Mahasirimongkol S, McLeod HL, Mockenhaupt M, Pacanowski M, Phillips EJ, Pinheiro S, Pirmohamed M, Sung C, Suwankesawong W, Trepanier L, Tumminia SJ, Veenstra D, Yuliwulandari R, Shear NH.

Clin Pharmacol Ther. 2018 Mar;103(3):390-394. doi: 10.1002/cpt.890. Epub 2017 Nov 6.

PMID:
29105735
10.

Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.

Marcath LA, Deal AM, Van Wieren E, Danko W, Walko CM, Ibrahim JG, Weck KE, Jones DR, Desta Z, McLeod HL, Carey LA, Irvin WJ Jr, Hertz DL.

Pharmacogenet Genomics. 2017 Nov;27(11):402-409. doi: 10.1097/FPC.0000000000000311.

PMID:
28877533
11.

Sink or Collaborate: How the Immersive Model Has Helped Address Typical Adolescent and Young Adult Barriers at a Single Institution and Kept the Adolescent and Young Adult Program Afloat.

Reed DR, Oshrine B, Pratt C, Fridgen O, Elstner C, Wilson L, Soliman H, Lee MC, McLeod HL, Shah B, Donovan KA, Pabbathi S, Turney M, Binitie O, Healy C, Nieder M, Shaw PH, Galligan A, Letson GD, Stern M, Quinn GP, Davies S.

J Adolesc Young Adult Oncol. 2017 Dec;6(4):503-511. doi: 10.1089/jayao.2017.0051. Epub 2017 Aug 4. No abstract available.

12.

Prospect for immune checkpoint blockade: dynamic and comprehensive monitorings pave the way.

Wang W, Liu J, He Y, McLeod HL.

Pharmacogenomics. 2017 Aug;18(13):1299-1304. doi: 10.2217/pgs-2017-0053. Epub 2017 Jul 26.

PMID:
28745931
13.

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

Rotroff DM, Pijut SS, Marvel SW, Jack JR, Havener TM, Pujol A, Schluter A, Graf GA, Ginsberg HN, Shah HS, Gao H, Morieri ML, Doria A, Mychaleckyi JC, McLeod HL, Buse JB, Wagner MJ, Motsinger-Reif AA; ACCORD/ACCORDion Investigators.

Clin Pharmacol Ther. 2017 Jul 24. doi: 10.1002/cpt.798. [Epub ahead of print]

PMID:
28736931
14.

EBV infection and MSI status significantly influence the clinical outcomes of gastric cancer patients.

Shen H, Zhong M, Wang W, Liao P, Yin X, Rotroff D, Knepper TC, Mcleod HL, Zhou C, Xie S, Li W, Xu B, He Y.

Clin Chim Acta. 2017 Aug;471:216-221. doi: 10.1016/j.cca.2017.06.006. Epub 2017 Jun 7.

PMID:
28601671
15.

Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort.

Gillis NK, Hicks JK, Bell GC, Daly AJ, Kanetsky PA, McLeod HL.

J Invest Dermatol. 2017 Sep;137(9):2021-2023. doi: 10.1016/j.jid.2017.05.010. Epub 2017 May 23. No abstract available.

PMID:
28549953
16.

Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial.

Marvel SW, Rotroff DM, Wagner MJ, Buse JB, Havener TM, McLeod HL, Motsinger-Reif AA; The ACCORD/ACCORDion Investigators.

PeerJ. 2017 May 2;5:e3187. doi: 10.7717/peerj.3187. eCollection 2017.

17.

Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma.

Knepper TC, Freeman ML, Gibney GT, McLeod HL, Russell JS.

JAMA Dermatol. 2017 Jun 1;153(6):607-609. doi: 10.1001/jamadermatol.2017.0187. No abstract available.

PMID:
28384659
18.

Bedside Back to Bench: Building Bridges between Basic and Clinical Genomic Research.

Manolio TA, Fowler DM, Starita LM, Haendel MA, MacArthur DG, Biesecker LG, Worthey E, Chisholm RL, Green ED, Jacob HJ, McLeod HL, Roden D, Rodriguez LL, Williams MS, Cooper GM, Cox NJ, Herman GE, Kingsmore S, Lo C, Lutz C, MacRae CA, Nussbaum RL, Ordovas JM, Ramos EM, Robinson PN, Rubinstein WS, Seidman C, Stranger BE, Wang H, Westerfield M, Bult C.

Cell. 2017 Mar 23;169(1):6-12. doi: 10.1016/j.cell.2017.03.005.

19.

Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.

Vela CM, Knepper TC, Gillis NK, Walko CM, McLeod HL, Hicks JK.

Pharmacotherapy. 2017 Sep;37(9):1043-1051. doi: 10.1002/phar.1917. Epub 2017 Apr 2.

PMID:
28235141
20.

Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.

Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, Gillis NK, Mason NT, McLeod HL, Walko CM.

Oncologist. 2017 Feb;22(2):144-151. doi: 10.1634/theoncologist.2016-0195. Epub 2017 Feb 8.

21.

Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib.

Walko CM, Aubert RE, La-Beck NM, Clore G, Herrera V, Kourlas H, Epstein RS, McLeod HL.

Oncologist. 2017 Feb;22(2):208-212. doi: 10.1634/theoncologist.2016-0233. Epub 2017 Feb 6.

22.

American Society of Clinical Oncology Value Framework: Importance of Accurate Toxicity Data.

Jim HS, McLeod HL.

J Clin Oncol. 2017 Apr 1;35(10):1133-1134. doi: 10.1200/JCO.2016.69.2079. Epub 2017 Feb 6. No abstract available.

PMID:
28165908
23.

Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer.

Jia F, Teer JK, Knepper TC, Lee JK, Zhou HH, He YJ, McLeod HL.

Mol Diagn Ther. 2017 Apr;21(2):179-185. doi: 10.1007/s40291-016-0250-z.

PMID:
28039579
24.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.

Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agúndez J, Wingard JR, McLeod HL, Klein TE, Cross SJ, Caudle KE, Walsh TJ.

Clin Pharmacol Ther. 2016 Dec 16. doi: 10.1002/cpt.583. [Epub ahead of print] Erratum in: Clin Pharmacol Ther. 2018 Feb;103(2):349.

PMID:
27981572
25.

Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.

Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E.

Lancet Oncol. 2017 Jan;18(1):112-121. doi: 10.1016/S1470-2045(16)30627-1. Epub 2016 Dec 4.

PMID:
27927582
26.

Somatic cancer variant curation and harmonization through consensus minimum variant level data.

Ritter DI, Roychowdhury S, Roy A, Rao S, Landrum MJ, Sonkin D, Shekar M, Davis CF, Hart RK, Micheel C, Weaver M, Van Allen EM, Parsons DW, McLeod HL, Watson MS, Plon SE, Kulkarni S, Madhavan S; ClinGen Somatic Cancer Working Group.

Genome Med. 2016 Nov 4;8(1):117.

27.

The pharmacogenomics of drug resistance to protein kinase inhibitors.

Gillis NK, McLeod HL.

Drug Resist Updat. 2016 Sep;28:28-42. doi: 10.1016/j.drup.2016.06.008. Epub 2016 Jul 5. Review.

28.

Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway.

Zhou C, Chen X, Zeng W, Peng C, Huang G, Li X, Ouyang Z, Luo Y, Xu X, Xu B, Wang W, He R, Zhang X, Zhang L, Liu J, Knepper TC, He Y, McLeod HL.

Oncotarget. 2016 Oct 18;7(42):68314-68327. doi: 10.18632/oncotarget.11599.

29.

Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.

Hertz DL, Deal A, Ibrahim JG, Walko CM, Weck KE, Anderson S, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Graham M, Peppercorn JM, Jones DR, Desta Z, Flockhart DA, Evans JP, McLeod HL, Carey LA, Irvin WJ Jr.

Oncologist. 2016 Jul;21(7):795-803. doi: 10.1634/theoncologist.2015-0480. Epub 2016 May 25.

30.

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.

Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL.

Clin Cancer Res. 2016 Oct 1;22(19):4890-4900. Epub 2016 May 3.

31.

Effects of quercetin on pharmacokinetics of cefprozil in Chinese-Han male volunteers.

Jia FF, Tan ZR, McLeod HL, Chen Y, Ou-Yang DS, Zhou HH.

Xenobiotica. 2016 Oct;46(10):896-900. doi: 10.3109/00498254.2015.1132792. Epub 2016 Feb 29.

PMID:
26928207
32.

A comparison of DMET Plus microarray and genome-wide technologies by assessing population substructure.

Jackson JN, Long KM, He Y, Motsinger-Reif AA, McLeod HL, Jack J.

Pharmacogenet Genomics. 2016 Jan 1. [Epub ahead of print]

33.

Metabolic Correction in Patients Sample with Diabetes: Clinical Outcomes and Costs Reductions.

Miranda-Massari JR, Rodríguez-Gómez JR, González MJ, Cidre C, Duconge J, Marín H, Grace K, McLeod HL.

Int J Diabetes Res. 2016;5(5):92-101.

34.

Clinical Implications of Opioid Pharmacogenomics in Patients With Cancer.

Bell GC, Donovan KA, McLeod HL.

Cancer Control. 2015 Oct;22(4):426-32. Review.

PMID:
26678969
35.

The potential anticancer effect of beta-blockers and the genetic variations involved in the interindividual difference.

He RH, He YJ, Tang YJ, Zhou HH, McLeod HL, Liu J.

Pharmacogenomics. 2016;17(1):74-9. doi: 10.2217/pgs.15.152. Epub 2015 Dec 14. Review.

PMID:
26652861
36.

Integrated patient and tumor genetic testing for individualized cancer therapy.

Hertz DL, McLeod HL.

Clin Pharmacol Ther. 2016 Feb;99(2):143-6. doi: 10.1002/cpt.294. Epub 2015 Nov 25.

PMID:
26537014
37.

Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting.

Kalman LV, Agúndez J, Appell ML, Black JL, Bell GC, Boukouvala S, Bruckner C, Bruford E, Caudle K, Coulthard SA, Daly AK, Del Tredici A, den Dunnen JT, Drozda K, Everts RE, Flockhart D, Freimuth RR, Gaedigk A, Hachad H, Hartshorne T, Ingelman-Sundberg M, Klein TE, Lauschke VM, Maglott DR, McLeod HL, McMillin GA, Meyer UA, Müller DJ, Nickerson DA, Oetting WS, Pacanowski M, Pratt VM, Relling MV, Roberts A, Rubinstein WS, Sangkuhl K, Schwab M, Scott SA, Sim SC, Thirumaran RK, Toji LH, Tyndale RF, van Schaik R, Whirl-Carrillo M, Yeo K, Zanger UM.

Clin Pharmacol Ther. 2016 Feb;99(2):172-85. doi: 10.1002/cpt.280. Epub 2015 Nov 20. Review.

38.

Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations.

Jittikoon J, Mahasirimongkol S, Charoenyingwattana A, Chaikledkaew U, Tragulpiankit P, Mangmool S, Inunchot W, Somboonyosdes C, Wichukchinda N, Sawanpanyalert P, He Y, McLeod HL, Chantratita W.

J Hum Genet. 2016 Feb;61(2):119-27. doi: 10.1038/jhg.2015.115. Epub 2015 Oct 1.

PMID:
26423926
39.

PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics.

Alvarellos ML, McDonagh EM, Patel S, McLeod HL, Altman RB, Klein TE.

Pharmacogenet Genomics. 2015 Dec;25(12):622-30. doi: 10.1097/FPC.0000000000000170. Review. No abstract available.

40.

Evaluating the role of admixture in cancer therapy via in vitro drug response and multivariate genome-wide associations.

Jack J, Havener TM, McLeod HL, Motsinger-Reif AA, Foster M.

Pharmacogenomics. 2015;16(13):1451-63. doi: 10.2217/PGS.15.85. Epub 2015 Aug 28.

41.

Budget impact analysis of CYP2C19-guided voriconazole prophylaxis in AML.

Mason NT, Bell GC, Quilitz RE, Greene JN, McLeod HL.

J Antimicrob Chemother. 2015 Nov;70(11):3124-6. doi: 10.1093/jac/dkv224. Epub 2015 Aug 1.

42.

Single-Nucleotide Polymorphisms in Cytochrome P450 2E1 (CYP2E1) 3'-Untranslated Region Affect the Regulation of CYP2E1 by miR-570.

Nakano M, Mohri T, Fukami T, Takamiya M, Aoki Y, McLeod HL, Nakajima M.

Drug Metab Dispos. 2015 Oct;43(10):1450-7. doi: 10.1124/dmd.115.065664. Epub 2015 Jul 21.

43.

Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial.

He YJ, Winham SJ, Hoskins JM, Glass S, Paul J, Brown R, Motsinger-Reif A, McLeod HL.

Pharmacogenomics J. 2016 Jun;16(3):243-8. doi: 10.1038/tpj.2015.52. Epub 2015 Jul 21.

PMID:
26194361
44.

Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).

Dressler LG, Deal AM, Owzar K, Watson D, Donahue K, Friedman PN, Ratain MJ, McLeod HL.

J Natl Cancer Inst. 2015 Jul 9;107(10). pii: djv188. doi: 10.1093/jnci/djv188. Print 2015 Oct.

45.

Accuracy of SNPs to predict risk of HLA alleles associated with drug-induced hypersensitivity events across racial groups.

He Y, Hoskins JM, Clark S, Campbell NH, Wagner K, Motsinger-Reif AA, McLeod HL.

Pharmacogenomics. 2015 Jul;16(8):817-24. doi: 10.2217/pgs.15.41. Epub 2015 Jun 17.

PMID:
26083016
46.

Global implementation of genomic medicine: We are not alone.

Manolio TA, Abramowicz M, Al-Mulla F, Anderson W, Balling R, Berger AC, Bleyl S, Chakravarti A, Chantratita W, Chisholm RL, Dissanayake VH, Dunn M, Dzau VJ, Han BG, Hubbard T, Kolbe A, Korf B, Kubo M, Lasko P, Leego E, Mahasirimongkol S, Majumdar PP, Matthijs G, McLeod HL, Metspalu A, Meulien P, Miyano S, Naparstek Y, O'Rourke PP, Patrinos GP, Rehm HL, Relling MV, Rennert G, Rodriguez LL, Roden DM, Shuldiner AR, Sinha S, Tan P, Ulfendahl M, Ward R, Williams MS, Wong JE, Green ED, Ginsburg GS.

Sci Transl Med. 2015 Jun 3;7(290):290ps13. doi: 10.1126/scitranslmed.aab0194. Review.

47.

Pharmacogenomic assessment of Mexican and Peruvian populations.

Marsh S, King CR, Van Booven DJ, Revollo JY, Gilman RH, McLeod HL.

Pharmacogenomics. 2015;16(5):441-8. doi: 10.2217/pgs.15.10.

48.

In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.

Hertz DL, Snavely AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S, Weck KE, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Peppercorn JM, Evans JP, Jones DR, Desta Z, Flockhart DA, Carey LA, Irvin WJ Jr.

Br J Clin Pharmacol. 2015 Nov;80(5):1122-30. doi: 10.1111/bcp.12665. Epub 2015 Aug 2.

49.

Heritage-specific mechanisms for cancer adverse reactions: one gene does not explain the world.

Knepper TC, McLeod HL.

J Clin Oncol. 2015 Apr 10;33(11):1230-1. doi: 10.1200/JCO.2014.60.1740. Epub 2015 Mar 9. No abstract available.

PMID:
25753435
50.

Precision medicine to improve the risk and benefit of cancer care: genetic factors in vincristine-related neuropathy.

McLeod HL.

JAMA. 2015 Feb 24;313(8):803-4. doi: 10.1001/jama.2015.1086. No abstract available.

PMID:
25710656

Supplemental Content

Loading ...
Support Center